{"id":54036,"date":"2012-10-11T14:29:42","date_gmt":"2012-10-11T14:29:42","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/nanoguardians-on-dose-nanoencryption-brand-protection-technology-to-be-presented-at-aaps-annual-meeting.php"},"modified":"2012-10-11T14:29:42","modified_gmt":"2012-10-11T14:29:42","slug":"nanoguardians-on-dose-nanoencryption-brand-protection-technology-to-be-presented-at-aaps-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nano-medicine\/nanoguardians-on-dose-nanoencryption-brand-protection-technology-to-be-presented-at-aaps-annual-meeting.php","title":{"rendered":"NanoGuardian&#39;s On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting"},"content":{"rendered":"<p><p>    SKOKIE, IL--(Marketwire - Oct 11, 2012) - NanoGuardian, a    division of NanoInk, Inc. that delivers on-dose brand    protection solutions to the pharmaceutical industry to fight    counterfeiting and illegal diversion, announced today that it    will give a poster presentation at the American Association of    Pharmaceutical Scientists (AAPS) Annual Meeting and Exhibition,    which is being held on October 14 - 18, at McCormick Place in    Chicago. The abstract, \"Can Nanofabrication be used to Combat    Counterfeit Medicines by Applying On-dose Authentication    Features without Disrupting the Integrity of the Medicine?\"    will be presented on Monday, October 15, from 1:30 to 4:30 p.m.    in Hall F by Bjoern Rosner, director of research and    development, brand protection for NanoGuardian.  <\/p>\n<p>    \"Counterfeit medicines have become such a problem that    pharmaceutical manufacturers are evaluating how to best ensure    the integrity of their medicines for patients early in the drug    development process,\" said Dean Hart, chief commercial officer    of NanoGuardian. \"The AAPS poster presentation will demonstrate    that NanoGuardian's NanoEncryption technology can be used to    incorporate highly sophisticated nanoscale, authentication, and    tracing features directly on film-coated tablets, gelatin    capsules, and vial caps without affecting the dissolution or    stability of the medication -- important considerations in the    development and commercialization of a new medication.\"  <\/p>\n<p>    NanoGuardian's NanoEncryption technology is the only on-dose,    multi-layered, brand protection solution that enables    pharmaceutical manufacturers to authenticate and trace every    single dose, from plant to patient. NanoGuardian's Closed-Loop    Protection Program combines the on-dose authentication and    tracing benefits of NanoEncryption technology with a proactive    supply chain auditing program to identify counterfeit or    illegally diverted pharmaceuticals entering the global supply    chain as early as possible.  <\/p>\n<p>    NanoGuardian fights both counterfeiting and illegal diversion    with a single technology that can be used to protect capsules,    tablets, vial caps, and single-use syringes providing a layered    security of overt, covert, and forensic features. The overt and    covert security features allow dose-level authentication at any    point in the supply chain, while the forensic and nano-scale    NanoCodes provide comprehensive tracing information on each and    every dose. NanoGuardian's technology provides a strong benefit    over other on-dose technologies given that NanoGuardian's    security features are implemented with no additional material    or chemicals being added to the medication.  <\/p>\n<p>    As evidence of the rapidly growing problem of counterfeit    pharmaceuticals, a recent report from the U.S. Customs and    Border Protection and the U.S. Immigration and Customs    Enforcement noted that the domestic value of counterfeit    pharmaceutical seizures in fiscal year 2011 rose by more than    $11 million, an increase of almost 200 percent. The    implications for victims of counterfeit drugs are extremely    serious, often resulting in unexpected side effects, severe    allergic reactions and even death.  <\/p>\n<p>    AAPS provides a dynamic international forum for the exchange of    knowledge among scientists to enhance their contributions to    health. It offers timely scientific programs, ongoing    education, opportunities for networking, and professional    development. More information is available at:     <a href=\"http:\/\/www.aaps.org\" rel=\"nofollow\">http:\/\/www.aaps.org<\/a>.  <\/p>\n<p>    About NanoGuardian NanoGuardian, a    division of NanoInk, Inc., focuses exclusively on delivering    brand protection solutions to fight illegal diversion and    counterfeiting. Anchored by NanoInk's novel NanoEncryption    technology, NanoGuardian enables manufacturers to authenticate    and trace the integrity of their products across the supply    chain. More information about NanoGuardian is available at        <a href=\"http:\/\/www.nanoguardian.net\" rel=\"nofollow\">http:\/\/www.nanoguardian.net<\/a>.  <\/p>\n<p>    NanoInk, NanoGuardian, NanoEncryption and the NanoGuardian    logo are trademarks or registered trademarks of NanoInk,    Inc.  <\/p>\n<\/p>\n<p>Continue reading here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/nanoguardians-dose-nanoencryption-brand-protection-133000688.html;_ylt=A2KJjajI13ZQlzgA5hT_wgt.\" title=\"NanoGuardian&#39;s On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting\">NanoGuardian&#39;s On-Dose NanoEncryption Brand Protection Technology to Be Presented at AAPS Annual Meeting<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SKOKIE, IL--(Marketwire - Oct 11, 2012) - NanoGuardian, a division of NanoInk, Inc.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nano-medicine\/nanoguardians-on-dose-nanoencryption-brand-protection-technology-to-be-presented-at-aaps-annual-meeting.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-54036","post","type-post","status-publish","format-standard","hentry","category-nano-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/54036"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=54036"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/54036\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=54036"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=54036"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=54036"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}